Cellectar Biosciences, Inc. (CLRB) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Selectar Biosciences (CLRB) Q1 2026: $140M Financing Unlocks Phase III WM Launch and Accelerated Approval Path
June 17, 2026
-
CLRB Q2 2025: $45M Confirmatory Study Cost Anchors Accelerated Approval Path for Lead Radiopharma
June 16, 2026
-
Selectar Biosciences (CLRB) Q3 2025: $12.7M Financing Extends Runway, Regulatory Milestones Accelerate Iopofacine Path
June 16, 2026
-
CLRB Q4 2025: R&D Spend Falls 57% as Regulatory Milestones Unlock Accelerated Approval Path
June 15, 2026
-
CLRB Q4 2025: R&D Spend Drops 57% as Regulatory Milestones Drive Pipeline Momentum
June 15, 2026